ANI Pharmaceuticals (ANIP) vs Damora Therapeutics (DMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Damora Therapeutics (DMRA) has outperformed ANI Pharmaceuticals (ANIP) over the past year, gaining 38.5% versus a loss of 14.0%. Over five years, ANIP leads with a +68.1% price change compared with -68.8% for DMRA. ANI Pharmaceuticals is the larger company by market cap ($1.56 billion vs $1.44 billion), about 1.1 times the size.
On valuation, Damora Therapeutics trades at a lower trailing P/E (13.6x vs 13.9x for ANI Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | DMRA |
|---|---|---|
| Share price | $68.55 | $23.22 |
| Market cap | $1.56B | $1.44B |
| 1-day change | -0.84% | -4.44% |
| YTD return | -13.16% | +0.91% |
| 1-year return | -14.01% | +38.46% |
| 5-year return | +68.14% | -68.83% |
| P/E ratio (TTM) | 13.90 | 13.58 |
| Forward P/E | 6.72 | — |
| EPS (TTM) | $4.93 | $1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $883.37M | — |
| Revenue growth (YoY) | +43.78% | — |
| Net income (latest FY) | $78.34M | $-209.84M |
| Gross margin | 61.36% | — |
| Operating margin | 12.58% | — |
| Net margin | 8.87% | — |
| 52-week high | $87.76 | $38.33 |
| 52-week low | $67.14 | $15.76 |
| Distance from 52-week high | -21.89% | -39.41% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +50.81% | +101.46% |
| Average volume | 420.66K | 584.28K |
| Shares outstanding | 22.72M | 61.90M |
| Employees | 970 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMRA has outperformed ANIP by 52.5 percentage points over the past year.
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ANIP vs DMRA FAQ
Which is bigger, ANI Pharmaceuticals or Damora Therapeutics?
ANI Pharmaceuticals (ANIP) is larger, with a market capitalization of $1.56B compared with $1.44B for Damora Therapeutics (DMRA).
Which stock has performed better over the past year, ANIP or DMRA?
DMRA returned +38.46% over the past 12 months, compared with -14.01% for ANIP (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ANIP or DMRA?
DMRA has the lower trailing P/E at 13.6, versus 13.9 for ANIP. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are ANI Pharmaceuticals and Damora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.